Redeye updates its estimates and fair value range following Energy Save’s Q3 2023/2024 report.
Adj. EBITDA of GBP 2m in line with pre-annoucement (ABGSCe 3m) We trim sales but raise '24e EBIT fro...
Redeye leaves a comment following the Magle Group’s announced public offer to acquire Amniotics earl...
FDA aligns with Ph 3 design presented at IRLAB's 2023 CMD Design compatible with earlier Ph 2b, to c...
Movinn published on March 22nd the company’s Annual Report for 2023.
Huddlestock announced on Friday, March 22nd, that the company's client Stackby.
Redeye comments on the public offer to acquire Amniotics and the short-term capital obtained yesterd...
Redeye provides its initial comments following Smart Eye’s directed share issue of SEK150m, announce...
Redeye provides a research update on Scandinavian ChemoTech following the Q4 2023 report and the ret...
Nytt obligationslån Vi återupptar vår bevakning av Orexo efter att bolaget emitterat ett nytt säkers...
Brilliant Future, med en kund- och medarbetarundersökningsplattform, ökade nettoomsättningen till 89...
A diversified M&A play on civic infrastructure 1) Rapid growth, 2) deleveraging, 3) 15% growth & 12%...
Redeye updates its view on Flexion Mobile following its Q4 2023 report.
FY'24 guidance reiterated as expected; better FCF the main surprise Progress on path to profitabilit...
Redeye comments on Sleep Cycle’s Capital Markets Day (CMD), including the revised financial targets.
Guides for 34-42% FY'24 ARR growth (vs. ABGSCe at 30%) No outlook comments - we await the annual rep...
The recent scientific paper in Neurotherapeutics discusses the encouraging preclinical studies focus...
ARR and P&L headline items known, FCF better vs. ABGSCe FY'24 guidance reiterated (as expected) Expe...
Redeye comments on MGI’s record sales figures for February, representing an organic growth of 25%, u...
To be entitled to profit sharing for 2023 you can not be a part of any variable pay program, you mus...